Results 281 to 290 of about 213,634 (311)

Angiotensin II type 2 receptor effect on microvascular hydraulic permeability

Journal of Surgical Research, 2004
Angiotensin II (Ang II) is a potent vasoconstrictor that modulates microvascular permeability. Angiotensin II type 1 (AT1) and type 2 (AT2) receptors have been described with subsequent development of their respective antagonists. We hypothesized that the AT2 receptor modulates microvascular permeability.Hydraulic permeability (L(p)) was measured in ...
Christopher R, Newton, Brian, Curran, Gregory P, Victorino   +2 more
openaire   +2 more sources

Role of Type 1 and Type 2 Angiotensin Receptors in Angiotensin II–Induced Cardiomyocyte Hypertrophy

Hypertension, 1996
We compared the ability of angiotensin II (Ang II) to induce hypertrophy of neonatal rat ventricular myocytes with that of endothelin-1. Over 72 hours, Ang II (1 μmol/L) increased the ratio of protein to DNA by less than 10%, whereas endothelin-1 (100 nmol/L) produced a 28% increase.
G W, Booz, K M, Baker
openaire   +2 more sources

Type-1 and type-2 angiotensin II receptors in fetal rat brain

European Journal of Pharmacology, 1991
Brain angiotensin II receptors were located in 18-day-old rat embryos by quantitative autoradiography. In the nucleus of the solitary tract and choroid plexus, binding was displaced by the type-1 antagonist DuP 753. In the inferior olive, paratrigeminal and hypoglossal nuclei, binding was displaced by the type-2 antagonist CGP 42112 A.
K, Tsutsumi, M, Viswanathan, C, Strömberg, J M, Saavedra   +3 more
openaire   +2 more sources

Angiotensin II Type 2 Receptor (AT2R) in Glomerulogenesis

2019
Les données épidémiologiques indiquent que le diabète maternel est associé de manière significative aux anomalies congénitales des reins et des voies urinaires (CAKUT), ce qui implique un risque accru de CAKUT chez la progéniture des mères diabétiques par rapport à la population globale.
openaire   +1 more source

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Type-2 Angiotensin II Receptor

2020
openaire   +1 more source

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Peter Schellongowski   +2 more
exaly  

Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes

Kidney International Supplements, 2022
Peter R Rossing
exaly  

The Adrenomedullary Angiotensin II Type 2 Receptor

2014
R. Nostramo, A. Tillinger, J.M. Saavedra, L. Serova, R. Kvetnansky, E.L. Sabban   +5 more
openaire   +1 more source

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Rujul Parikh, Sagar Lonial
exaly